IP Library Granted Patent US 8,461,119
Granted Patent B2
US 8,461,119 · App. 10/652,407 · Granted Jun 11, 2013

Agents that modulate Eph receptor activity

Inventors: Elena B. Pasquale (San Diego, CA); Mitchell Koolpe (San Diego, CA); Keith K. Murai (Candiac, CA)
Assignee: The Burnham Institute
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,461,119
App. No.
10/652,407
Granted
Jun 11, 2013
Kind
B2
Abstract

Novel agents are described that bind to Eph receptors. Methods of using these agents to modulate the activity of Eph receptors, stimulate apoptosis, and deliver therapeutic agents are also described. Methods of screening for agents capable of selectively binding to Eph receptors are also described.

Claims (15)

1. An isolated peptide which selectively binds to the extracellular domain of a member of the Eph receptor family, wherein the isolated peptide comprises the amino acid sequence of SEQ ID NO:2.

2. A composition comprising the isolated peptide of claim 1 linked to p53 or pRB, and a pharmaceutical carrier.

3. A composition comprising:

the isolated peptide of claim 1 linked to a chemotherapeutic alkylating agent; and

a pharmaceutical carrier.

4. The composition of claim 3 , wherein the chemotherapeutic alkylating agent is melphalan or chlorambucil.

5. A composition comprising:

the isolated peptide of claim 1 linked to an anti-metabolite compound; and

a pharmaceutical carrier.

6. The composition of claim 5 , wherein the chemotherapeutic anti-metabolite compound is 5-fluorouracil or 5-fluorouridine.

7. The isolated peptide of claim 1 , wherein the isolated peptide is capable of inhibiting phosphorylation of MAP kinase (MAPK).

8. The isolated peptide of claim 1 , wherein the isolated peptide is capable of stimulating tyrosine phosphorylation of the EphA2 receptor.

9. The isolated peptide of claim 1 , wherein said member of the Eph receptor family is EphA2.

10. A composition comprising the isolated peptide of claim 1 linked to a radionuclide selected from the group consisting of 90 Y, 67 Cu, 111 Ln, 113m Ln, 67 Ga, 99m Tc, 51 Cr, 197 Hg, 203 Hg, 169 Yb, 85 Sr, and 87 Sr.

11. An isolated peptide which selectively binds to the extracellular domain of a member of the Eph receptor family, wherein the isolated peptide consists of the amino acid sequence of SEQ ID NO:2.

Assignments (4)
CHANGE OF NAME Recorded Oct 8, 2020
From: THE BURNHAM INSTITUTE
To: BURNHAM INSTITUTE FOR MEDICAL RESEARCH
Reel/Frame 054030/0487 →
CHANGE OF NAME Recorded Oct 8, 2020
From: BURNHAM INSTITUTE FOR MEDICAL RESEARCH
To: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
Reel/Frame 054030/0815 →
CHANGE OF NAME Recorded Oct 8, 2020
From: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
To: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
Reel/Frame 054031/0281 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 22, 2004
From: PASQUALE, ELENA B.; KOOLPE, MITCHELL; MURAI, KEITH K.
To: BURNHAM INSTITUTE, THE
Reel/Frame 014453/0057 →
Continuity (2)
Provisional Application 60413242 · Sep 24, 2002
Related Publication 20040180823A1 · Sep 16, 2004